



IDT Australia ships first generic temozolomide capsules to USA

... major milestone, marking the entry of IDT's new generic range into the US market, more to follow this financial year

... Mayne Pharma to distribute under profit share arrangement

... AUD205 million addressable market¹

02 November 2016, Melbourne: IDT Australia Ltd (IDT) has today shipped the first of its new proprietary generic pharmaceutical products to its US distribution partner, Mayne Pharma Group Limited. Brain cancer drug temozolomide is one of 25 generic products in IDT's growing generic product portfolio, and this shipment marks the realization of the Company's push to extend its share of the value chain via the ownership of generic finished pharmaceutical products. The range as a whole currently has an addressable market of approximately USD750 million.

Temozolomide will be distributed in the USA under an agreement with Mayne Pharma. Under the terms of the agreement IDT will receive payment upon shipment on usual commercial terms for the cost of goods, with the companies also sharing equitably in the gross profit upon sale of the goods to the market, balanced on a quarterly basis.

Paul MacLeman, Managing Director said: "This is a real milestone moment for IDT as we continue to pursue the manufacture of sophisticated generic pharmaceuticals that allow us to earn more appropriate margins compared to contract manufacturing. The sale of our CMAX clinical trial facility in Adelaide will allow us to further populate our generics pipeline which already features 25 drugs. We are actively searching for new opportunities with significant addressable markets that play to our manufacturing strengths and we will announce these to the market as they are finalised. IDT is also looking to leverage its generics manufacturing capabilities into other offshore markets, mirroring our success in the US."

The strategy for revenue and profit growth via the development of IDT's own drug portfolio has been in development for approximately two years and this year will see the launch of a number of other IDT products into the US market. The next products expected for launch this FY are pindolol, doxazosin and leucovorin, followed next year by prazosin, mexilitine, nefazadone and others. The Company is also assessing options for generic sales growth into other geographical markets.

ENDS

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
John Beveridge
(03) 9620 3333

¹ IMS Health, MAT September 2016

About IDT

IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 Temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based adjacent to the new Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.